Baxter to Use GenOdyssee's Protein Platform for Hemophilia Research | GenomeWeb
NEW YORK (GenomeWeb News) — Protein therapy products maker GenOdyssee today said it will provide Baxter with its technology, intellectual property, and integrated processes.
 
Under the agreement, Baxter will use these platforms to discover "novel blood clotting factors" in the course of its hemophilia research, and will develop and market any "commercially viable products" resulting from the partnership.
 
Financial terms of the agreement were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.